The phase I study of T-DXd was conducted in TNBC patients with HER2-low tumors (defined as IHC 1+/ISH negative or 2+/ISH negative), as well as strong HER2-positive breast cancers [35]. Here, ERBB2 is linked to breast carcinoma.